Hope of alternative treatment for osimertinib-relapsed lung cancer patients


Sumary of Hope of alternative treatment for osimertinib-relapsed lung cancer patients:

  • Additional targeted options Byoung Chul Cho, M.D., Ph.D., Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, South Korea, and lead study investigator, said:.
  • “Typically, patients whose disease no longer responds to osimertinib therapy would have little opportunity to seek additional treatments, other than chemotherapy..
  • However, the durable responses we are seeing with the combination of amivantamab and lazertinib suggest an additional targeted option may be possible..
  • The most common adverse events were predominantly Grade 1-2 and included infusion-related reactions (78%), rash (acneiform dermatitis, 51% + rash, 27%) and paronychia (49%)….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.